United States
Angola Brazil Burundi Cameroon Colombia Cote d’Ivoire DRC El Salvador Eswatini Ethiopia Georgia Ghana Guatemala Honduras Haiti Kazakhstan Kenya Kyrgyzstan Lesotho Liberia Malawi MauritaniaMozambique Myanmar Namibia Nigeria Panama Peru Philippines Rwanda SenegalSierra Leone South Africa South Sudan Tajikistan Tanzania Uganda Ukraine United States Zambia Zimbabwe
United States
ICAP’s two research centers in New York, the Bronx Prevention Center and the Harlem Prevention Center, are hubs of research in New York City that have been historically underserved and disproportionately impacted by the HIV epidemic and, more recently, the COVID-19 epidemic. ICAP works with local community-based organizations, religious leaders, and advocates to promote community awareness of and engagement with the research studies.
Led by Wafaa El-Sadr, MD, MPH, MPA and Jessica Justman, MD, this work is supported through the ICAP at Columbia University Clinical Trials Unit (CTU). The ICAP CTU aims to support the design and implementation of research to address gaps in the global HIV response, including through clinical research sites in the Harlem, Bronx, and Eswatini.
The Community Advisory Board (CAB) for the ICAP Clinical Trials Unit (CTU) provides guidance and feedback on proposed studies, outreach strategies, feedback on study materials, and information regarding community perceptions of the potential or current research studies.
Current studies include investigations of antibody-mediated prevention using broadly neutralizing antibodies (bnAbs) to prevent HIV or COVID-19, an injectable long-acting pre-exposure prophylaxis (PrEP) option, mobile technologies to improve PrEP adherence, integrated care for people who inject opiates, HIV vaccine studies, and studies of COVID-19 immunity, vaccine efficacy, and treatment among others.
Through Columbia University, ICAP also supports additional COVID-19 surveys and various student fellowship programs, engaging students to participate in the design, implementation, and evaluation of ICAP-supported programs while working side-by-side with its experts.

Columbia Univesity
Mailman School of Public Health

Current Studies
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
No Projects
Soon to Launch
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
The LEXICON Study 2.0Districts (or national)New York City
Project Details
The LGBTQ+ Experience in COVID-19 NYC Study To assess the impact of COVID-19 on the lives and well-being of LGBTQ+ persons in NYC, the LEXICON study will conduct a community-based online
Project Details
Completed Studies
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
The LEXICON StudyDistricts (or national)New York City
Project Details
The LGBTQ+ Experience in COVID-19 NYC Study To assess the impact of COVID-19 on the lives and well-being of LGBTQ+ persons in NYC, the LEXICON study will conduct a community-based online
Project Details
The SILVER StudyDistricts (or national)New York City
Project Details
The SARS-CoV-2 Impact on Lives and Views of Elderly Residents Study To better understand the impact of COVID-19 on older adults living at home, the SILVER study conducted a phone survey
Project Details
Harlem Prevention Center

Current HPC Studies
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
CoVPN 3003 -The ENSEMBLE StudyDistricts (or national)Harlem
Project Details
Closed to enrollment and study follow-up Study to Assess the Efficacy and Safety of Ad26.COV2.S (the Johnson & Johnson COVID vaccine) for the Prevention of SARS-COV-2 mediated COVID-19 in Adults Aged
Project Details
Study to Assess the Efficacy and Safety of Ad26.COV2.S (the Johnson & Johnson COVID vaccine) for the Prevention of SARS-COV-2 mediated COVID-19 in Adults Aged 18 Years and Older
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04505722
https://clinicalresearch.itmat.upenn.edu/clinicaltrial/6568/covid19-covid-vaccine-covpn-3003-janssen/
CoVPN 3006Districts (or national)Harlem
Project Details
A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine Study to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in university students
Project Details
Study to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04811664
https://www.coronaviruspreventionnetwork.org/moderna-vaccine-university-study/
HPTN 091: I AM StudyDistricts (or national)Harlem
Project Details
HPTN 091 is a study assessing the feasibility, acceptability, preliminary impact of a multi-component strategy that provides HIV prevention services, gender-affirming hormone therapy, and Peer Health Navigation to improve pre-exposure
Project Details
Web Links:
https://www.hptn.org/research/studies/hptn091
HTPN 083: Give PrEP a ShotDistricts (or national)Harlem
Project Details
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB
Project Details
Closed to enrollment, in active study follow-up
Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094
https://www.hptn.org/research/studies/hptn083
https://giveprepashot.org/
HVTN 706 - The MOSAICO StudyDistricts (or national)Harlem
Project Details
HIV Vaccine Trials Network Open to enrollment Study of Heterologous Vaccine Regimen to prevent HIV-1 Infection among Cis-gender Men and Transgender Individuals who have Sex with Cis-gender Men and/or Transgender Individuals Web Links:
Project Details
Web Links:
https://clinicaltrials.gov/ct2/show/NCT03964415
https://www.hvtn.org/en/community/community-compass/vol19-issue2/mosaico.html
https://www.avac.org/trial/hpx-3002-hvtn-706-mosaico
Soon to Launch
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
Evergreen StudyDistricts (or national)Harlem
Project Details
A randomized, double-blind, placebo-controlled Phase 3 efficacy study of an Ad26.RSV.preF-based vaccine in the prevention of lower respiratory tract disease caused by RSV in adults aged 60 years and older.
Project Details
Completed HPC Studies
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
CoVPN 3502 The HEROIC StudyDistricts (or national)Harlem
Project Details
Closed to enrollment and study follow-up Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 More information:
Project Details
CoVPN 5002: The COMPASS StudyDistricts (or national)Harlem
Project Details
SARS- COV-2 Prevalence Study – to assess the prevalence of active and recovered COVID infections in the Harlem community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/
Project Details
Project Details
The ADAPT Study recruited men who have sex with men (MSM) and transgender women and was designed to identify oral pre-exposure prophylaxis (PrEP) pill-taking schedules that participants are more likely
Project Details
HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national)Harlem
Project Details
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study that tested the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV..
Project Details
HVTN130/HPTN089Districts (or national)Harlem
Project Details
Closed to enrollment and study follow-up A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies administered via intravenous infusion in healthy,
Project Details
HVTN405/HPTN1901: HIV Vaccine Trials NetworkDistricts (or national)Harlem
Project Details
Open to enrollment Characterizing SARS-CoV-2-specific immunity in convalescent individuals Report Links: https://clinicaltrials.gov/ct2/show/NCT04403880 https://www.hvtn.org/content/dam/hvtn/MEDIAROOM/study-fact-sheet_HVTN405-HPTN1901_v2.pdf
Project Details
PrEPared & Strong - Clinic-based PrEP for Black MSMDistricts (or national)Harlem
Project Details
This five-year, multi-method implementation study tested an enhanced PrEP adherence package against a standard package in a randomized clinical trial located in a community setting. The study compared the effectiveness
Project Details
Project Details
The STAR Study is a five-year study that tested the effectiveness of respondent-driven sampling to seek and recruit substance-using Black men who have sex with men (MSM) at high risk
Project Details
Bronx Prevention Center

Current BPC Studies
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
ACTIV-2/A5401: The ACTIV StudyDistricts (or national)Bronx
Project Details
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530
CoVPN 3002: The AstraZeneca StudyDistricts (or national)Bronx
Project Details
This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19 Closed to enrollment, follow up ongoing Web Links: https://clinicaltrials.gov/ct2/show/NCT04516746
Project Details
Closed to enrollment, follow up ongoing
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746
HPTN 094: The INTEGRA StudyDistricts (or national)Bronx
Project Details
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190
HTPN 083: Give PrEP a ShotDistricts (or national)Bronx
Project Details
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB
Project Details
Closed to enrollment, in active study follow-up
Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/
IMPOWER-022: The Merck Study (on hold)Districts (or national)Bronx
Project Details
A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1
Project Details
Making PrEP SmartDistricts (or national)Bronx
Project Details
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month
Project Details
Soon to Launch
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
No Projects
Completed BPC Studies
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
Global TA
PHIA
QICIP
CQUIN
GNCBP
OpCon
OPTIMIZE
HPTN
MTCT-Plus
MCAP
UTAP
TRACE
COVID
CTU
Project Location
All
Tajikistan
Brazil
Guatemala
Georgia
Haiti
China
Kazakhstan
Kyrgyzstan
Namibia
Nigeria
Rwanda
Central Asia
Burundi
Liberia
Philippines
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Colombia & Peru
Tanzania
Angola
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kenya
Ethiopia
Malawi
Sierra Leone
Zimbabwe
Mozambique
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
CoVPN 5002: The COMPASS StudyDistricts (or national)Bronx
Project Details
The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/
Project Details
Project Details
HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for
Project Details
HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national)Bronx
Project Details
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The
Project Details
Project Details
This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal
Project Details
Project Details
This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by
Project Details
ICAP in the United States
Program Start
2004
Key Technical Areas
-
Clinical Research and Trials
-
COVID-19 Research
- PrEP Research
- Surveys
- Sexually Transmitted Infections Research
Current Funders
- The Rockefeller Foundation
- The Samuels Foundation
- The New York Community Trust
ICAP Founder and Global Director
Dr. Wafaa El-Sadr, MD, MPH, MPA
Dr. Wafaa El-Sadr is the founder and director of ICAP and an international expert in epidemiology and research on the prevention and management of HIV, tuberculosis, and other infectious diseases. She is also the director of Columbia World Projects. For over three decades, she has advocated for families and communities most impacted by HIV and championed a collaborative, multidisciplinary approach to confronting the global epidemic.
Based at Columbia University, she leads ICAP’s portfolio of projects in 30 countries and manages a global team of over 2,000 staff. Under her leadership, ICAP has become a global leader in HIV and health systems strengthening. She is also the director of the Mailman School’s Global Health Initiative (GHI), which mobilizes the University community to address critical challenges in global health.
Jobs in the United States
For international ICAP job listings see careers at ICAPACITY